I. Pusic

发表

Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia.

F. Gao, F. Gao, P. Westervelt, 2020, Cancer discovery.

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

K. Gregory, Hema M Sundar, M. Deininger, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.

F. Gao, P. Westervelt, J. Dipersio, 2021, Leukemia research.

Economic evaluation of plerixafor for stem cell mobilization.

J. Dipersio, S. Kymes, K. Carson, 2012, The American journal of managed care.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report.

J. Ritz, J. Pidala, H. Greinix, 2021, Transplantation and cellular therapy.

Ixazomib for treatment of refractory chronic graft vs. host disease: A Chronic GVHD Consortium phase II trial: Ixazomib for chronic GVHD treatment.

W. Wood, B. Storer, J. Pidala, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Challenges in Conducting Studies in Chronic Graft-versus-Host Disease

S. Pavletic, I. Pusic, 2019, Clinical hematology international.

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

A. Logan, D. Miklos, M. Flowers, 2017, Blood.

Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.

F. Gao, R. Vij, P. Westervelt, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.

A. Logan, D. Miklos, M. Flowers, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

FAM treatment for new onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation

J. Pidala, Stephanie J. Lee, M. Flowers, 2016 .

Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.

B. Storer, J. Pidala, Stephanie J. Lee, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.

R. Vij, P. Westervelt, J. Dipersio, 2016, Leukemia research.

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

R. Vij, P. Westervelt, J. Dipersio, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Chronic Myeloid Leukemia, Version 2.2021

K. Gregory, Hema M Sundar, M. Deininger, 2020 .

Protective effect of CMV reactivation on relapse after allogeneic hematopoietic cell transplantation in AML patients is influenced by their conditioning regimen Blood Marrow

R. Vij, P. Westervelt, C. Abboud, 2014 .

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen

F. Gao, J. Welch, R. Vij, 2017, Cancer medicine.

A randomized phase-2 trial of pomalidomide in subjects failing prior therapy of chronic graft-versus-host disease.

D. Venzon, R. Gale, W. Figg, 2020, Blood.

The use of growth factors in hematopoietic stem cell transplantation.

J. Dipersio, I. Pusic, 2008, Current pharmaceutical design.

Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

W. Wood, B. Storer, J. Pidala, 2016, Blood.

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

A. Logan, D. Howard, J. Liesveld, 2021, Blood.

SARS-CoV-2 Omicron boosting induces de novo B cell response in humans

M. Diamond, S. Whelan, Julian Q. Zhou, 2022, bioRxiv.

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease

J. Dipersio, H. Khoury, D. Roberts, 2018, Bone Marrow Transplantation.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduce

N. Geller, P. Hari, D. Porter, 2019, The Lancet. Haematology.

Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia

Erica K. Barnell, Zachary L. Skidmore, O. Griffith, 2021, JCO precision oncology.

A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation

W. Wood, D. Miklos, B. Storer, 2015, Clinical Cancer Research.

Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia

O. Frankfurt, S. Kambhampati, H. Kantarjian, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.

R. Vij, P. Westervelt, J. Dipersio, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.

M. Bar, J. Wagner, J. Sierra, 2021, Transplantation and cellular therapy.

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.

F. Gao, P. Westervelt, J. Dipersio, 2021, Blood.

Measuring Therapeutic Response in Chronic Graft-versus-host-disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus- Host Disease: Iv. Response Criteria Working Group Report

Daniel Wolff, Anita Lawitschka, Sandra A. Mitchell, 2022 .

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Christopher A. Miller, R. Wilson, R. Fulton, 2016, The New England journal of medicine.

Germinal centre-driven maturation of B cell response to mRNA vaccination

S. Whelan, Julian Q. Zhou, Zhuoming Liu, 2022, Nature.

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Yi Bai, Jun Ma, Hui Wang, 2020, Research square.

Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.

Christopher A. Miller, R. Fulton, T. Ley, 2018, JCI insight.

Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells

J. Dipersio, I. Pusic, 2010, Current opinion in hematology.

HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation

P. Westervelt, J. Dipersio, T. Fehniger, 2016, Bone Marrow Transplantation.

Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia.

Christopher A. Miller, R. Fulton, D. Koboldt, 2015, Blood.

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

A. Ellebedy, J. Turner, A. Schmitz, 2021, Nature.

Phase-1/-2 study of pomalidomide in chronic GvHD

J. Dipersio, R. Gale, M. Rettig, 2016, Bone Marrow Transplantation.

Conservative management of pneumatosis intestinalis after allogeneic hematopoietic SCT

J. Dipersio, A. Ghobadi, I. Pusic, 2014, Bone Marrow Transplantation.

Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.

W. Wood, J. Pidala, Stephanie J. Lee, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning.

P. Westervelt, J. Dipersio, C. Abboud, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation

R. Vij, P. Westervelt, J. Dipersio, 2014 .

Letermovir discontinuation at D+100 after Allogeneic Stem Cell Transplant is associated with increased CMV-related mortality.

F. Gao, R. Vij, P. Westervelt, 2022, Transplantation and cellular therapy.

Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?

M. Milošević, D. Pulanić, S. Pavletic, 2016, Croatian medical journal.

Randomized Multicenter Trial of Sirolimus vs. Prednisone as Initial Therapy for Standard Risk Acute GVHD: BMT CTN 1501.

E. Leifer, M. Horowitz, J. Pidala, 2019, Blood.

Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant.

B. Storer, J. Pidala, Stephanie J. Lee, 2016, Annals of the American Thoracic Society.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

W. Wood, J. Pidala, E. Holler, 2018, Blood advances.

Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation

T. Druley, K. Trinkaus, J. Dipersio, 2020, Science Translational Medicine.

Cardio‐oncology care in the era of the coronavirus disease 2019 (COVID‐19) pandemic: An International Cardio‐Oncology Society (ICOS) statement

G. Curigliano, Jennifer E Liu, S. Szmit, 2020, CA: a cancer journal for clinicians.

Biomarker Panel for Chronic Graft-Versus-Host Disease.

Philip R. Gafken, Y. Ogata, B. Storer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention of graft versus host disease with Hematopoietic CellTransplantation with Reduced Intensity Conditioning—a comparison of threeprophylaxis regimens (tacrolimus/mycophenolate mofetil/cyclophosphamide,tacrolimus/methotrexate/bortezomib or tacrolimus/methotrexate/maraviroc) versustacrolimus/me

N. Geller, P. Hari, M. Pasquini, 2019 .

Germinal centre-driven maturation of B cell response to SARS-CoV-2 vaccination

Julian Q. Zhou, W. Middleton, A. Ellebedy, 2021, bioRxiv : the preprint server for biology.

Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.

B. Storer, J. Pidala, Stephanie J. Lee, 2016, Blood.

Association of Leukemia Cutis With Survival in Acute Myeloid Leukemia.

M. Anadkat, I. Pusic, Cynthia X Wang, 2019, JAMA dermatology.

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

L. Coussens, Z. DeFilipp, Stephanie J. Lee, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia.

J. Pidala, Stephanie J. Lee, M. Flowers, 2020, Blood advances.

Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids

A. Logan, D. Miklos, M. Flowers, 2016 .

Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival

J. Pidala, Stephanie J. Lee, M. Arora, 2021, Blood advances.

Amphiregulin Improves Stratification of the Refined Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN 0302/0802

W. Wood, J. Pidala, E. Holler, 2017 .

Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease

M. Bishop, A. Kessinger, I. Pusic, 2002, Bone Marrow Transplantation.

Case report Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease

A. Kessinger, I. Pusic, Bishop, 2002 .

A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML

J. Welch, R. Vij, P. Westervelt, 2013, American journal of hematology.

Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes

F. Gao, R. Vij, P. Westervelt, 2015 .

SARS-CoV-2 Omicron boosting induces de novo B cell response in humans

M. Diamond, S. Whelan, Julian Q. Zhou, 2023, Nature.

Acute Graft-versus-Host Disease: An Update on New Treatment Options

I. Pusic, M. Schroeder, D. Patel, 2023, Drugs.

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

F. Gao, M. Walter, R. Vij, 2022, Blood.

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

F. Gao, P. Westervelt, J. Dipersio, 2021, Blood.

Mutation Clearance after Transplantation for Myelodysplastic Syndrome

R. Fulton, T. Ley, J. Welch, 2018, The New England journal of medicine.

The use of ruxolitinib for acute graft‐versus‐host disease developing after solid organ transplantation

J. Dipersio, M. Jacobs, D. Byers, 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

R. Vij, L. Wartman, P. Westervelt, 2016, Leukemia & lymphoma.

Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation

B. Storer, J. Pidala, Stephanie J. Lee, 2015 .

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

P. Riedell, R. Vij, P. Westervelt, 2017 .

A Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplant.

M. Walter, R. Vij, P. Westervelt, 2023, Transplantation and cellular therapy.

Health Economic Outcome Analysis Of Stem Cell Mobilization With Granulocyte Colony-Stimulating Factor (G-CSF) Plus Plerixafor Versus G-CSF Alone In Preparation For Autologous Stem Cell Transplantation (ASCT) In Patients With Non-Hodgkin's Lymphomas (NHL)

J. Dipersio, S. Kymes, I. Pusic, 2010 .

Strengthening implementation guidelines for HIV service delivery: Considerations for future evidence generation and synthesis

Najam Ali Khan, R. Fulton, T. Ley, 2023, PLoS medicine.

A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML

J. Welch, R. Vij, P. Westervelt, 2013, American journal of hematology.

Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.

J. Pidala, M. Flowers, S. Pavletic, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Patient-reported treatment response in chronic graft-versus-host disease

J. Pidala, A. Im, M. Flowers, 2023, Haematologica.

45: Development of Antibodies to Self Antigens K-alpha-1 Tubulin and Collagen V in Patients with Chronic Graft Versus Host Disease

W. Shannon, J. Dipersio, T. Mohanakumar, 2008 .

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

A. Logan, D. Miklos, M. Flowers, 2017, Blood.

Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease

J. Dipersio, I. Pusic, M. Veeraputhiran, 2023, Bone marrow transplantation.

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

P. Westervelt, J. Dipersio, Julie K. Ritchey, 2023, Blood.

Ruxolitinib for steroid‐refractory acute graft‐versus‐host disease

P. Westervelt, J. Dipersio, M. Fiala, 2019, Transplant international : official journal of the European Society for Organ Transplantation.